JMJoana M. Mack

Joana M. Mack

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Joana M. Mack has a total of 70 co-authors. Here are the top co-authors by number of shared publications:

  • Shelley E. Crary

    University of Arkansas for Medical Sciences, Little Rock, Arkansas, United States

    9 shared publications
  • Bethany Verkamp

    Department of Pediatrics, Cincinnati Children’s Medical Center, Cincinnati, OH

    4 shared publications
  • Gresham T. Richter

    Arkansas Children's Hospital Little Rock Arkansas USA

    4 shared publications
  • Beverly Spray

    Arkansas Children's Research Institute, Little Rock, AR

    3 shared publications
  • David Becton

    Department of Pediatrics Division of Pediatric Hematology‐Oncology University of Arkansas for Medical Sciences Little Rock Arkansas

    2 shared publications
  • Kathleen Neville

    Department of Pediatrics Division of Hematology/Oncology University of Arkansas for Medical Sciences Little Rock Arkansas USA

    2 shared publications

Latest Publications

  • Open Access

    Impact of anticoagulation on quality of life in patients with slow-flow vascular malformations

    by Joana M. Mack, Shelley E. Crary, Julie Blatt, Beverly Spray, Alexandra Borst, Melisa Ruiz-Gutierrez, Sara Kreimer, Ionela Iacobas, Neeraja Swaminathan, Andrew Tran, et al.


  • Effects of Adoption of Race‐Neutral Predictive Equations on Spirometry Results in Children With Sickle Cell Disease

    by Zena Ghazala, Matthew Pertzborn, Macey Feimster, Chary Akmyradov, Joana Mack, Suzanne Saccente, Ariel Berlinski

    Background: Lung disease is a major cause of morbidity and mortality in children with sickle cell disease (SCD), a condition that is more common in individuals of African American descent. Spirometry is utilized in monitoring lung health. Recently, the American Thoracic Society recommended the use of race‐neutral predictive equations. We aimed to evaluate how the use of race‐neutral equations may affect spirometry results and interpretation in children with SCD.Methods: This retrospective study included children aged 5–21 years with SCD followed at Arkansas Children's Hospital (01/01/2000–06/30/2023) who had completed at least one spirometry. Percent predictive (pp) and z‐score values were calculated using race‐adjusted and race‐neutral predictive equations. Absolute and relative differences were calculated. Percent of subjects with forced expiratory volume in 1 s (FEV1) and forced vital capacity (FVC) with z‐score <‐1.645 and pp < 80%, and FEV1/FVC z‐score < −1.645 were compared. Severity of impairment based on z‐score was compared.Results: One hundred children completed 460 spirometries. Transitioning from race‐adjusted to race‐neutral equations resulted in [mean (SD)]: a decrease in ppFEV1 [−9.497% (2.8344)], FEV1 z‐score [−0.723 (0.2286)], ppFVC [−10.08% (3.3440)], FVC z‐score [−0.750 (0.2757)], FEV1/FVC z‐score [−0.057 (0.05461)], and an increase in ppFEV1/FVC [0.2785 (0.3921)]. Transitioning from race‐adjusted to race‐neutral equations resulted in an increase of impairment for FVC and FEV1 and a threefold increase in subjects with abnormal values.Conclusions: Adoption of race‐neutral reference equations resulted in a decrease in FEV1 and FVC values (z‐scores and percent predicted) and an increase in severity of impairment.


  • Sociodemographic Characteristics of Patients Seen at Vascular Anomaly Centers in the United States

    by Bryan A. Sisk, Whitney Eng, Jamie Aye, Joana Mack, Andrew Tran, Jayme Ogino, Erika Pearson, Joshua Bies, Gayle Smink, Sonal D. Shah, et al.

    Patients with vascular anomalies (VAs) require expert multidisciplinary care. No prior studies have characterized the sociodemographic characteristics across multiple VA centers. We collected data on 5783 patients receiving care at 20 VA centers between July 1, 2020 through December 31, 2022. Male patients were underrepresented compared to the state‐level census data at 17/20 centers. Black and Asian patients were underrepresented at 14/20 and 12/20 centers, respectively. The median distance to the hospital was 48 miles, and median age was 12.0 years. These data suggest that race, sex, age, and distance from the hospital could impede the ability to access expert VA care.


  • How we approach coagulopathy with vascular anomalies

    by Joana M. Mack, Shelley E. Crary

    Some vascular anomalies can present with challenging hematologic aberrations. Kaposiform hemangioendothelioma (KHE) may be complicated with Kasabach–Merritt phenomenon (KMP) and stagnant blood flow in slow‐flow malformations can promote activation and consumption of coagulation factors, which results in bleeding and clotting known as localized intravascular coagulopathy (LIC). These patients can experience significant morbidity secondary to pain due to thrombosis and are at higher risk of hematologic complications during surgical procedures. No standard of care has been established to prevent or manage these complications. This review focuses on the management of coagulopathy in children and adults with vascular anomalies.


  • Pharmacokinetics of bleomycin sclerotherapy in patients with vascular malformations

    by Joana M. Mack, Eric C. Peterson, Shelley E. Crary, Jeffery H. Moran, Kathleen Neville, C. D'Ann Pierce, Gresham T. Richter

    Bleomycin, a chemotherapy agent that inhibits synthesis of DNA, has been increasingly utilized in sclerotherapy for patients with vascular malformations. A serious long‐term risk of intravenous bleomycin is dose‐dependent interstitial pneumonitis. Little is known about absorption and circulating levels of bleomycin when used in sclerotherapy for patients with vascular malformations. This is an Institutional Review Board (IRB)‐approved prospective study on patients receiving bleomycin sclerotherapy in the management of vascular malformations. Depending on the type of vascular malformation, bleomycin was administered either in the lumen or interstitial space of the involved lesion. A bleomycin assay measured serum bleomycin plasma concentrations versus time at seven intervals following treatment. Pharmacokinetic parameters were obtained for each participant and included peak plasma concentration (Cmax), time to reach peak plasma concentration (Tmax), volume of distribution (Vd), elimination half‐life (t1/2), the volume of plasma cleared of the drug per unit time (CL), and total systemic exposure area under the curve (AUC). Fifteen patients were enrolled (5: lymphatic, 4: venous, 6: arteriovenous malformations). Bleomycin was administered interstitially (IS) in 11 patients and intraluminal (IL) in four; median age of 13 years (range: 2–67). Pharmacokinetic analysis revealed terminal elimination half‐life (t1/2λz) of 88.51 (±23.09) and 111.61 (±37.75) minutes for the IS and IL groups, respectively. Vd was 4.86 L (±6.74) and 1.55 L (±0.54) for the IS and IL groups, respectively. AUC was 53.9 (±23.45) and 129.17 (±93.57) mg min/L for the IS and IL groups, respectively. There were no statistically significant differences in t1/2λz, Vd, or AUC parameters between groups. Bleomycin is absorbed systemically when used as a sclerosant for vascular malformations when injected either IS or IL.


  • Pupil Size and Reactivity in Pediatric Patients With Sickle Cell Disease

    by Joana M. Mack, Sara Bs Frankowski, Bethany Verkamp, Shelley E. Crary, Beverly Spray, Lee Rt Crawley, Suzanne Saccente, Kathleen A. Md Neville

    Pupil size and reactivity have been studied to objectively measure pain utilizing pupillometry measurements. Given the challenges associated with treating vaso-occlusive pain in pediatric patients with sickle cell disease, better assessment tools are needed. The objective of this study is to establish normative values for pupil size and reactivity in pediatric patients with sickle cell disease with the hope that pupillometry can be used as a tool to objectively measure pain and response to treatment with analgesic medications. Readings were performed using a NeurOptics PLR-2000 pupillometer. Forty-four males and 38 females, all black, were studied. Their median age was 11 years (range: 2 to 21). When comparing our participants with white participants in a previously published pediatric study, there was a significant difference in maximum constriction velocity (t=3.45, P=0.009), maximum pupil size (t=−5.57 mm, Pt=−3.24, P=0.002). There was no significant difference in pupil size and reactivity between patients with sickle cell disease and black patients without the disease when compared with the previously published study. Therefore, further investigation of pupillometry within the black population during vaso-occlusive crisis and in the “well state” is warranted in pediatric patients with sickle cell disease.

  • Open Access

    Bleomycin Sclerotherapy Is Laboratory Monitoring Necessary?

    by Joana M. Mack, Austin N. DeHart, Bethany Verkamp, P. Spencer Lewis, Shelley E. Crary

    Objectives: Bleomycin is a chemotherapeutic agent also used as a sclerosant for the management of vascular malformations. Although effective and with a low complication profile, the safety and monitoring necessary for this indication is still controversial. This study examines routine periprocedural laboratory results on a cohort of patients undergoing bleomycin sclerotherapy. Methods: Retrospective chart review of prospectively collected data was performed on patients who underwent bleomycin sclerotherapy for vascular malformations from 2011 to 2018. Complete blood count and liver function were assessed before and after sclerotherapy. Results: Forty-six patients were identified who underwent a total of 71 sclerotherapy sessions with bleomycin. A median dose of 5 U/m2 of bleomycin was used per procedure (8 U total). No difference between preprocedure and postprocedure values was detected for white blood cell count (7.7–7.9; P = .63) or absolute neutrophil count (4009–4414; P = .20). A nominal difference was found in hemoglobin (12.7–13.0; P = .001), hematocrit (37.0–38.6; P = .001), and platelet counts (278–302; P = .001). No patient had absolute neutrophil count levels below 500 cells/μL. On liver function tests, no change was detected for direct bilirubin (0.19–0.17; P = .4). A small decrease in total bilirubin (0.49–0.41; P = .004), aspartate aminotransferase (32.1–26.9; P < .001), and alanine aminotransferase (31.2–24.3; P < .001) was shown. Conclusion: This study suggests that laboratory assessment of immune and liver function, as commonly performed in chemotherapy protocols, is not required following intralesional bleomycin sclerotherapy. Clinically relevant abnormalities are unlikely to be detected as demonstrated in this cohort of patients with vascular malformations.


  • Open Access

    How we approach coagulopathy with vascular anomalies.

    by Joana Mack, Shelley Crary

    Some vascular anomalies can present with challenging hematologic aberrations. Kaposiform hemangioendothelioma (KHE) may be complicated with Kasabach-Merritt phenomenon (KMP) and stagnant blood flow in slow flow malformations can promote activation and consumption of coagulation factors which results in bleeding and clotting known as localized intravascular coagulopathy (LIC). These patients can experience significant morbidity secondary to pain due to thrombosis and are at higher risk of hematologic complications during surgical procedures. No standard of care has been established to prevent or manage these complications. This review focuses on the management of coagulopathy in children and adults with vascular anomalies.

  • Analyzing coagulation dynamics during treatment of vascular malformations with thromboelastography

    by Joana M. Mack, C. D'ANn Pierce, Gresham T. Richter, Beverly J. Spray, Richard Nicholas, P. Spencer Lewis, David Becton, Shelley E. Crary

    Background/Objectives: Slow‐flow vascular malformations are abnormal vessels that can lead to activation and consumption of coagulation factors and thrombosis, known as localized intravascular coagulopathy (LIC). Most clinical and research evidence of vascular malformation hemostasis relies on conventional coagulation studies, which may not provide a complete picture. Thromboelastograpy (TEG) is a tool that can provide real‐time assessment of a patient's coagulation dynamics, and may allow for a more individualized treatment approach. We hypothesized that patients with slow‐flow vascular malformations will have changes in TEG parameters peri‐procedure that will help predict blood product or medication administration.Design/Methods: Institutional Review Board approved prospective study of patients with slow‐flow vascular malformations undergoing a sedated, minor procedure. TEG and conventional coagulation studies were obtained preprocedure, 15 min, and when possible, at 30 min after the start of the procedure.Results: Twenty‐five patients were enrolled. Median age was 15 years (range 3‐47 years). Procedures included laser and/or sclerotherapy. There were no changes in TEG parameters from baseline to 15 min or 30 min. The following decreased from baseline to 15 min: fibrinogen 313 to 287 mg/dL (P = .001), D‐dimer 1.3 to 1.1 mg/L (P = .02), hemoglobin 12.8 to 11.8 g/dL (P = .001), and platelet count 272 000 to 256 000 (P = .006). No patient had a bleeding/thrombotic complication during or within 1 week postprocedure.Conclusion: We saw no change in TEG parameters or bleeding or clotting complications despite significant numerical changes in conventional coagulation profiles, suggesting that conventional studies may not be as useful in determining risks of bleeding or thrombotic complications peri‐procedure for minor procedures.


  • Open Access

    Pupil Size and Reactivity in Pediatric Patients with Sickle Cell Disease

    by Joana Mack, Sara Frankowski, Bethany Verkamp, Shelley Crary, Beverly Spray, Lee Crawley, Suzanne Saccente, Kathleen Neville

    Background/Objectives: Pupil size and reactivity have been studied in adult and pediatric populations to objectively measure pain which showed that pupillometry is a promising biomarker for pain measurement. Vaso-occlusive crisis, is a common complication of sickle cell disease (SCD) and better assessment tools are needed. The objective of this study is to establish normative values for pupil size and reactivity in pediatric patients with SCD with the hope that pupillometry can be used as a tool to objectively measure pain and response to treatment. Design/Methods: Institutional review board (IRB) approved prospective study enrolled 82 patients with SCD. Readings were performed using a NeurOptics PLR-2000 pupillometer. The following measures were collected: resting pupil size, % change in pupil size, pupil constriction velocity, and pupil dilation velocity. Results: Forty-four males and 38 females, all black, were studied. Median age was 11 years (range:2-21). The mean minimum and maximum pupil sizes were 3.52mm and 5.08mm, respectively. The mean dilation velocity and maximum constriction velocity were 1.03mm/s and -4.48mm/s, respectively. When comparing our participants with white participants in a previously published pediatric study, there was a significant difference in maximum constriction velocity, maximum pupil size, and minimum pupil size.1 There was no significant difference when comparing means for these parameters. Conclusion: There was no significant difference in pupil size and reactivity between patients with SCD and black patients without the disease. Further investigation of pupillometry within the black population during vaso-occlusive crisis and in the “well state” is warranted in pediatric patients with SCD.